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Abstract
Introduction: Cervical cytology is a well- stablished cervical cancer screen-
ing method. However, due to the anatomical continuity of the genital tract, 
it can also detect signs of endometrial disease. Our aim was to estimate the 
sensitivity of cervical cytology in endometrial cancer detection and prognosis 
in a large population over a 30- year period in a large academic tertiary hospi-
tal in Spain.
Methodology: We performed a search for women diagnosed with endometrial 
cancer from 1990 to 2020, who were surgically treated and had a previous cervical 
cytology result. Information Technologies Department databases from Bellvitge 
University Hospital and the Screenwide case– control study's database were used. 
Cervical cytology results were classified as abnormal when squamous lesions, 
glandular atypia or malignant cells were identified.
Results: Overall, we evaluated 371 women with endometrial cancer and a docu-
mented cervical cytology performed within 3 years previous to surgical treatment. 
Overall, the sensitivity of cervical cytology for endometrial cancer detection was 
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1  |  INTRODUCTION
In 2018, endometrial cancer (EC) was one of the most 
common gynaecological cancers which accounted for 8.4 
cases per 100,000 women worldwide.1 EC has been classi-
cally classified into two groups: type I (endometrioid), the 
most common one, which usually shows a good prognosis 
and type II (non- endometrioid), a less common heteroge-
neous subtype (10%– 15%), which shows a poor progno-
sis.2 Although the dualistic classification system is widely 
used, a new classification system proposed by The Cancer 
Genome Atlas (TCGA) Consortium based on molecular 
features is starting to be integrated into clinical practise.3,4 
Due to the expected rise in obesity rates and ageing of the 
population, the EC burden is likely to increase over the 
next years.2,5
Cervical cytology is a well- stablished test in cervical 
cancer screening programmes, which have helped to reach 
a large reduction in cervical cancer incidence and mor-
tality.6,7 The anatomical continuity of the uterine cavity 
with the cervix makes the cervical cytology also accessible 
to evaluate signs of disease shed from the endometrium. 
Therefore, collecting cervical cells may also allow sam-
pling of abnormal endometrial cells, if any. Likewise, sev-
eral retrospective studies have shown abnormal cells of 
suspected endometrial origin at cervical cytological find-
ings in 45% of cases with EC on average.8 Nevertheless, 
recent molecular advances in the genomic, epigenomic 
and proteomic exploitation of these samples could offer 
a benefit in the early detection of EC, with sensitivities 
up to ≈80%.9 We performed a retrospective evaluation to 
examine the sensitivity of routine cervical cytology among 
women with EC in a large academic tertiary hospital in 
Spain between 1990 and 2020.
2  |  MATERIALS AND METHODS
The study was based on women with EC diagnosed in dif-
ferent time periods in the Bellvitge University Hospital 
identified using three databases: two retrospective data-
bases from the Information and Technologies Department 
(1990– 2018) and a data set from the Screenwide case– 
control study (2017– 2020). Databases from the Information 
and Technologies Department include automatically ex-
tracted data collected in the electronic medical pathologi-
cal files of patients. Data from the case– control study are 
extracted individually from the participants' medical files 
by an experienced investigator. All data are linked using 
the regional medical identification number. The Bellvitge 
University Hospital is a reference tertiary hospital for 
more than 1,800,000 people and more than 2,500,000 peo-
ple for high- grade EC referrals.
Women surgically treated for EC and who had previ-
ous cervical cytology performed within 3 years from the 
hysterectomy date were identified in the two retrospec-
tive databases: one contained data from 1990 to 2014 
and another one with data from 2014 to 2018. Data were 
also extracted from the Screenwide case– control study in 
which consecutive women with a confirmed diagnosis 
of incident EC were prospectively enrolled from 2017 to 
2020 and pre- operative cervical cytology was collected. 
Extracted data from the electronic medical records in-
cluded histology, grade, stage and presence of symptoms 
(only for prospective cases), date of hysterectomy, tumour 
extent and lymphatic affection when available. We also 
extracted cytology results and the dates on which cervical 
cytology were performed. If more than one cervical cytol-
ogy was performed within the selected period, the most 
recent cytology before the hysterectomy was selected. We 
excluded cases with cervical cytology performed uniquely 
before 3 years from the hysterectomy date and those with 
unknown dates of hysterectomy (Figure S1).
Conventional Pap tests were used up to 2010 and 
liquid- based (ThinPrep®) afterwards. Cervical cytology 
diagnoses were recoded as normal versus abnormal. 
Abnormal diagnoses included: (1) squamous lesions 
(atypical squamous cells of undetermined significance 
[ASCUS], low- grade squamous intra- epithelial lesions 
[LSIL], high- grade squamous intra- epithelial lesions 
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25.6%. Several clinico- pathological characteristics, such as non- endometrioid his-
tology and a higher stage, were correlated with higher sensitivity.
Discussion: We observed a low sensitivity of cervical cytology to effectively diag-
nose endometrial cancer. However, recent technological advances using genom-
ics and epigenomics may offer a promising perspective to detect endometrial 
cancer with high sensitivity in these cervical specimens.
K E Y W O R D S
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[HSIL] and atypical squamous cells cannot exclude HSIL 
[ASC- H]); (2) glandular atypia, including atypical glan-
dular cells of undetermined significance (AGUS) or (3) 
malignant cells. Bethesda system to classify cytology re-
sults was used in our centre from 2000 onwards. We cate-
gorised as pre- operative those cervical cytology performed 
within 2 months from the intervention date. We estimated 
the overall sensitivity as the number of women with true- 
positive results (abnormal cervical cytology results) di-
vided by the number of women with endometrial cancer 
(true positives + false negatives). We analysed results by 
several factors including histology and tumour extent. We 
applied Fisher's exact tests for proportions to compare 
several clinico- pathological characteristics. Confidence 
intervals (CIs) were calculated using a binomial exact test 
(- cii- command in Stata). All statistical analyses were per-
formed using Stata v.16.10
3  |  RESULTS
Between 1990 and 2020, we identified 1521 women di-
agnosed with EC at the Bellvitge University Hospital. 
Three hundred and seventy- one of them (24.4%) had a 
documented cervical cytology performed within 3  years 
from the hysterectomy date. Included women had similar 
histology than women without a documented Pap within 
3 years from a hysterectomy (p value >.05), although they 
were younger at diagnosis (p value <.01). The age of pa-
tients ranged between 28 and 91 years old, and 96.8% were 
older than 45 years. An abnormal cervical cytology result 
was observed in 25.6% (95% CI: 21.2%– 30.4%) (N = 95) of 
included women. Of them, 48 had malignant cells, 41 dis-
played atypical glandular cells including AGUS and 6 had 
squamous lesions (Table 1). No statistically significant dif-
ferences were observed between results from retrospective 
and prospective data sets (24.6% vs. 26.9%, respectively; p 
value = .633) (Table S1).
Sensitivity was higher for non- endometrioid histology 
compared with endometrioid cancers (37.3% vs. 21.2%, p 
value = .002, Table 2). Statistically significant differences 
were observed according to grades (11.8%, 32.7% and 
34.8% for Grades 1, 2 and 3, respectively, p value <.001). 
Likewise, sensitivity was higher for those with advanced 
stages (II/III/IV) in comparison with stage I (55.0% vs. 
16.2%, p value <.001). Statistically significant differences 
were also observed for tumour extent (16.2%, 68.0% and 
38.3% for tumour extent T1, T2 and T3, respectively, p 
value <.001) and lymphatic affection (20.8% and 43.8% 
for N0 and N1– 2, respectively, p value  =  .007). No sta-
tistically significant differences were observed according 
to the time period of diagnosis (p value = .895). Most of 
the cytology were performed pre- operatively: 58.4% of the 
cytology were performed within ≤2 months from hyster-
ectomy. We found statistically significant differences by 
time from hysterectomy (31.6% vs. 17.6%, for cytology per-
formed within ≤2 months and >2 months from hysterec-
tomy, respectively, p value = .003, Table 2). No statistically 
significant differences were observed according to the 
presence of symptoms (p value = .798, Table S2).
4  |  DISCUSSION
Cervical cytology is a well- stablished tool that has al-
lowed the implementation of effective cervical screen-
ing programmes and has contributed to achieve a great 
reduction of incidence and mortality.6,7 Consequently, 
George Papanicolaou, the inventor of the Pap test, be-
came interested at the end of his career in the diagnos-
tic value of cervico- vaginal smears in the detection of EC. 
Unfortunately, he acknowledged that the cytology was 
not equally satisfactory for EC detection compared with 
cervical malignancies, and therefore, it has never been 
proposed as a screening approach neither a down- staging 
approach until early tumour molecular markers are being 
identified in cervical scrapes.11,12
We observed that only 25.6% of women with EC had 
abnormal cervical cytology before hysterectomy. Around 
half of these lesions already suggested a malignancy. 
The sensitivity of cervical cytology was higher for non- 
endometrioid histology and more advanced cancers but 
still with low performance. Sensitivity to detect EC ob-
served in this study was low, although results may be rel-
evant considering the transition in several regions from 
cytology- based to primary HPV testing in cervical cancer 
screening programmes. A recent systematic review of the 
literature showed that 45% of women with EC had an ab-
normal Pap before surgery or diagnosis.8 However, Castle 
Cervical cytology results N (%) [95% CI]
Normal 276 (74.4%) [69.6%−78.8%]
Abnormal 95 (25.6%) [21.2%−30.4%]
Squamous lesionsa 6 (1.6%) [1.0%−3.5%]
Glandular atypia (including 
AGUS)
41 (11.1%) [8.0%−14.7%]
Malignant 48 (12.9%) [9.7%−16.8%]
Abbreviations: AGUS, atypical glandular cells of undetermined significance; 
CI, confidence interval.
aSquamous lesions include: atypical squamous cells of undetermined 
significance (ASCUS), low- grade squamous intraepithelial lesions (LSIL), 
high- grade squamous intraepithelial lesions (HSIL) and atypical squamous 
cells, cannot exclude HSIL (ASC- H).
T A B L E  1  Findings in patients with endometrial cancer and 
cervical cytology performed within 3 years previous to surgical 
treatment
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et al., with a large sample size (n = 3414 EC cases), ob-
served recently that only 12.65% of EC were preceded by 
abnormal cytology.13 While some of the studies included 
in the meta- analyses referred to pre- operative cytology, 
Castle et al. included routine cytology for cervical cancer 
screening, which could contribute to the observed low 
sensitivity in this study. We searched for all cytology in the 
Bellvitge University Hospital and observed that 17.6% of 
cytology performed >2  months from hysterectomy were 
abnormal, which is in line with Castle et al., findings. 
Other factors could have also contributed to the observed 
low sensitivity in our study. We did not observe normal 
endometrial cells among post- menopausal women in our 
centre. Analyses restricted to atypical and malignant cells 
in this systematic review revealed a sensitivity of 44%,8 
which is still higher to that observed in our study. A long 
debate exists on the report of benign- appearing endome-
trial cells, and 2014 Bethesda system14 recommends re-
porting normal endometrial cells among women 45 years 
or older, although this cut- off age is still under debate.15 
On the other hand, the pathologist knowledge on the EC 
status may also have influenced results, but unfortunately, 
we cannot evaluate this information.
To our knowledge, this is the study evaluating the lon-
gest period of time (1990– 2020), and one of the largest 
analyses on the topic. Altogether, this allows a reasonable 
statistical power to evaluate the sensitivity of cervical cy-
tology in EC detection. The centre covers a large popula-
tion of the region, although it may treat more advanced 
cancers in comparison to other hospitals, which could 
result in an over- estimation of the sensitivity of cervical 
cytology for EC. However, we observed a relatively low 
sensitivity of cervical cytology in EC. This may be in part 
because women who did not undergo surgery were not 
included. These women may have more advanced can-
cers and therefore may be more likely to have abnormal 
cytology results. Part of the data was retrospective, and 
the databases were not designed for this study purpose. 
Retrospective data, in particular oldest data, may have 
misclassification issues due to the lack of reports from 
some pathologists or certain variables. For instance, retro-
spective databases did not contain information on tumour 
spread, and therefore, analysis on stage was restricted to 
prospective data. Prospective data may be more reliable, 
although we did not observe statistically significant differ-
ences in sensitivity between retrospective and prospective 
data sets.
In conclusion, our analyses revealed an overall low sen-
sitivity of cervical cytology in EC detection. The sensitivity 
of cervical cytology was significantly higher among non- 
endometrioid histology compared with endometrioid his-
tology. Similarly, other clinico- pathological characteristics 
related to a high stage of the tumour were also associated 
with significantly higher sensitivity. Contrary, sensitivity was 
lower when cervical cytology were performed >2 months 
from hysterectomy, rather than pre- operatively. Based on 
our estimates, the current sensitivity of the cervical cytology 
is too low to effectively diagnose EC, although recent tech-
nological advances using genomics and epigenomics may 
offer a promising perspective to detect EC with a higher sen-
sitivity in these cervical specimens.
T A B L E  2  Sensitivity of cervical cytology for endometrial cancer 














Endometrioid 212 (78.8%) 57 (21.2%) .002
Non- endometrioid 64 (62.8%) 38 (37.3%)
Grade
Grade 1 134 (88.1%) 18 (11.8%) <.001
Grade 2 33 (67.3%) 16 (32.7%)
Grade 3 76 (65.5%) 40 (34.8%)
Stagec 
I 93 (83.8%) 18 (16.2%) <.001b 
II/III/IV 18 (45.0%) 22 (55.0%)
Tumour extent
T1 218 (83.9%) 42 (16.2%) <.001b 
T2 8 (32.0%) 17 (68.0%)
T3 29 (61.7%) 18 (38.3%)
Lymphatic affection 
(node)
N0 183 (79.2%) 48 (20.8%) .007
N1 and N2 18 (56.3%) 14 (43.8%)
Time period of 
diagnosis
1990– 2009 95 (75.4%) 31 (24.6%) .895
2010– 2017 66 (75.0%) 22 (25.0%)
2018– 2020 105 (72.9%) 39 (27.1%)
Time lag between 
cervical cytology 
and hysterectomy
≤2 months 145 (68.4%) 67 (31.6%) .003
>2 months 131 (82.4%) 28 (17.6%)
Note: Numbers do not always add up due to missing data.
Abbreviation: IQR, inter- quartile range.
aAbnormal Pap results include squamous lesions, atypical glandular cells of 
undetermined significance (AGUS), atypia and malignant lesions.
bFisher's exact test.
cData available only for the prospective study.
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